TrialEuropean heart journal2025

Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial.

Christiane E Angermann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.